Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashley Rogers

Pain Medicine Atlanta, GA Medical Doctor

NPI 1841436060 CMS profile 1284720

550 Peachtree St Ne, Atlanta, GA 30308

Open in the dashboard

General payments

$5,414

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Rogers of Atlanta, GA is reported in the CMS Open Payments database as having received $5,414 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $287 5
2023 General $110 1
2022 General $321 7
2021 General $736 10
2019 General $3,958 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Rogers
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Ashley Rogers were reported at $287. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Ashley Rogers Pain Medicine median Middle half National median
2019 $3,958 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $736 $399 $112–$1,219 $132
2022 $321 $455 $137–$1,484 $149
2023 $110 $484 $128–$1,495 $160
2024 $0 $498 $131–$1,540 $164
2025 $287 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $2,076 3 payments
  2. Abbott Laboratories $1,944 15 payments
  3. Nevro Corp. $525 8 payments
  4. Medtronic, Inc. $192 3 payments
  5. BIOTRONIK NRO, Inc. $184 3 payments
  6. SPR Therapeutics, Inc $170 3 payments
  7. Curonix LLC $94 1 payment
  8. Chiesi USA, Inc. $91 1 payment
  9. E.R. Squibb & Sons, L.L.C. $87 1 payment
  10. Puma Biotechnology, Inc. $51 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $2,000 2 payments
  2. Food and Beverage $1,724 31 payments
  3. Travel and Lodging $1,689 6 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMED $2,000 2 payments
  2. Proclaim Family of SCS IPGs $1,766 11 payments
  3. Omnia $306 6 payments
  4. Prospera $184 3 payments
  5. SPRINT PNS System $170 3 payments
  6. PROCLAIM $141 1 payment
  7. OSTEOCOOL RF ABLATION $132 1 payment
  8. Senza $110 1 payment
  9. Senza Spinal Cord Stimulation System $109 1 payment
  10. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $94 1 payment
  11. Other $394 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,591

Median for Anesthesiology: 322

Drug cost

$104,816

Median for Anesthesiology: $8,738

Branded share of claims

28.4%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 63 $39,144
Buprenorphine Generic 105 $32,649
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 198 $5,538
Gabapentin Generic 247 $5,468
Lidocaine Generic 22 $3,023
Pregabalin Generic 128 $2,956
Diclofenac Sodium Generic 29 $2,093
Fentanyl Generic 11 $2,065
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 153 $2,048
Baclofen Generic 46 $2,041

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$48,217

Medicare's payments for the services billed

Medicare patients

247

Average age 73

Services billed

686

146 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 37%
Depression 37%
Diabetes 35%
Chronic kidney disease 32%
Heart failure 26%
Cancer 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record